I would only differ from your hypothesis in that I

I would only differ from your hypothesis in that I think the FDA wants to look at the longer end points even tho they approved the 28 day protocol. I sense that the discussions are about how to provide this info and what the remedy would be for CytoDyn should a 60 day endpoint be wanted by FDA. To me this scenario would suggest that Leronlimab produced efficacious results at 28 days and Cytodyn is wanting some interim authorization to start to commercialize Leronlimab and come up with a work around to provide results from a longer end point. Of course I am just using a crystal ball.